Advances in nuclear medicine rely on a delicate balance between science, technology and clinical application. For over 20 years, Trasis has been meeting this challenge by providing concrete solutions for hospitals and radiopharmacies around the world. Behind this journey lies a solid partnership : Jean-Luc Morelle and Gauthier Philippart.
They began working together in the early 2000s, when a shared insight brought them together: they both believe that technology can simplify, safeguard and democratise procedures essential to patient care, in the diagnosis and treatment of cancer.
Their strength lies in their clear synergy. Jean-Luc Morelle embodies the company’s technological soul: he visualises, designs and anticipates scientific developments. Gauthier Philippart, on the other hand, foresees user needs, lends structure to development, manages the company and creates the conditions for consistent and effective growth. “Our synergy, reinforced further by our experience and our age difference, has been decisive,” says Jean-Luc Morelle. “We never make decisions alone. We challenge each other a lot, but always with the same goal in mind: to grow Trasis without losing sight of what matters.”
A responsive and pragmatic approach
When entering the market “the most difficult part was to identify gaps that would address unmet needs. Our products were created based on the actual needs of radiopharmacists. We learnt by actively listening, observing and correcting,” says Jean-Luc Morelle. This practical approach also became their signature style: to innovate, for sure, but by starting with the grassroots! “We aimed to understand current needs while anticipating future needs and obstacles, but also by keeping a steady course: turning complex issues into simple, trustworthy and scalable solutions that would prove beneficial for medical teams and, ultimately, for patients”, says Gauthier Philippart.
Company of the year 2025!
“It is an extraordinary recognition for Trasis! It honours 20 years of perseverance and the day-today work of our teams. It is not a culmination of something, but rather a boost of energy for what lies ahead in the future.” A future that is already starting to take shape: international expansion - including securing a crucial market in China by setting up a joint venture in Beijing - new products and significant investment into Ans, with wide-ranging ambitions: “we want to double our turnover, continue contributing to an effective nuclear medicine sector and expand without losing our identity.”
WAB Magazine
